We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Gets Priority FDA Review for Pneumococcal Vaccine
Pfizer Gets Priority FDA Review for Pneumococcal Vaccine
Even in the midst of the COVID-19 pandemic, not all vaccine news has to do with the coronavirus: Pfizer said this week that the FDA has accepted for priority review a biologics license application (BLA) the company filed for its vaccine against a form of streptococcus that can lead to fatal infections.